3B BlackBio Q3 FY26 Revenue ₹99Cr; Guides 10-15% Growth Amid M&A

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorSimar Singh|Published at:
3B BlackBio Q3 FY26 Revenue ₹99Cr; Guides 10-15% Growth Amid M&A
Overview

3B BlackBio DX Limited reported a significant 9M FY26 revenue of ₹99.06 crores, driven by strong export performance and the consolidation of its recent Coris BioConcept acquisition. The company guides for 10-15% revenue and EBITDA growth for the full year, signalling a strategic shift towards global expansion and product diversification. However, rising competition and integration costs remain key areas to monitor.

3B BlackBio DX Posts Robust 9M Revenue Growth, Eyes US Market Entry Post-Acquisition

9M revenue reached ₹99.06 crores; Full-year revenue and EBITDA growth guided at 10% to 15%.

Reader Takeaway: Revenue surges on strong exports; rising competition and integration costs pose pressure.

What just happened (today’s filing)

3B BlackBio DX Limited has reported strong financial performance for the nine months ended December 31, 2025 (9M FY26), with revenue climbing to ₹99.06 crores, a substantial increase from ₹64.80 crores in the same period last year. This growth was bolstered by its export business, which is expanding at over 20% and now reaches 70 countries. The company's Q3 FY26 consolidated revenue stood at ₹50.35 crore, up from ₹25.39 crore year-on-year, contributing to a net profit of ₹22.44 crore.

The EBITDA for the nine-month period was impacted by one-time merger and acquisition expenses related to its recent Coris BioConcept acquisition. The company also highlighted its estimated 12% to 15% market share in the Indian molecular diagnostic reagent market, which has a Total Addressable Market (TAM) of ₹400 to ₹500 crores.

Why this matters

The company is in a significant transition phase, integrating its recent acquisitions to build a global diagnostic footprint. Success in entering the crucial US market, pending regulatory approvals, and launching new diagnostic machines could be major growth catalysts. This strategic expansion aims to diversify revenue streams beyond its traditional Indian market and agrochemical business.

The backstory (grounded)

3B BlackBio DX Limited, formerly Kilpest India Limited, changed its name in August 2023 following a merger. The company specializes in PCR-based molecular diagnostic kits, enzymes, and reagents, with a history dating back to 1972. In a significant strategic move, 3B BlackBio DX acquired Coris BioConcept, a Belgian innovator in rapid lateral flow test kits, in late August 2025. This acquisition, along with its subsidiary TRUPCR Europe, aims to enhance its global diagnostics capabilities by combining TRUPCR's PCR-based assays with Coris's rapid test technology, expanding its reach across Europe, Asia, and Africa.

What changes now

Shareholders can anticipate a potential listing on the NSE post-March 2026, subject to audited financial results and meeting capital/net worth requirements. The integration of Coris BioConcept is expected to drive international sales, with a target for the Belgian subsidiary to achieve 2-4% positive EBITDA in the next fiscal year. The company is also focused on launching a new sample-to-answer machine in the upcoming quarter and navigating the complex US FDA registration process for Coris. Management is keenly focused on maintaining margins amidst increasing competition.

Risks to watch

Seasonal dependence can skew quarterly growth figures, leading management to prefer longer-term assessments. The Coris acquisition carries risks, including a finite 'sunset contract' (HAT) which management aims to offset with US market entry. The viability of Next-Generation Sequencing (NGS) products remains a concern due to low margins, with the company keeping its focus on technology relevance rather than profitability for this segment. Rising competition from biochemistry and ELISA players, and stretched industry credit periods of 3-5 months, also present operational challenges.

Peer comparison

The Indian molecular diagnostics market is dominated by global giants like Roche Diagnostics and Abbott Laboratories, which have extensive R&D and distribution networks. Closer domestic competitors include Transasia Bio-Medicals and Tulip Diagnostics, offering broader IVD solutions. 3B BlackBio DX is carving a niche with its specialized PCR and NGS offerings and a growing international presence, distinct from larger, more generalized diagnostic chains like Thyrocare Technologies or Dr. Lal PathLabs.

Context metrics (time-bound)

  • 9M FY26 consolidated revenue stood at ₹99.06 crores, compared to ₹64.80 crores in 9M FY25.
  • Q3 FY26 consolidated revenue was ₹50.35 crore, an increase from ₹25.39 crore in Q3 FY25.
  • The acquired subsidiary Coris Holding SRL contributed ₹24.01 crore to consolidated sales in 9M FY26.
  • M&A advisory fees related to the Coris acquisition amounted to ₹1.39 crore in 9M FY26.
  • The company targets 10-15% revenue and EBITDA growth for the full FY26.

What to track next

Investors will closely monitor the progress of the US FDA registration for Coris BioConcept, with visibility expected by July. The successful launch of the new sample-to-answer machine and the financial turnaround of the Coris segment towards positive EBITDA are key triggers. The company's ability to secure an NSE listing after audited results and its strategy to manage margin pressure amidst intensifying competition will also be critical indicators.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.